Association between beta-interferon exposure and hospital events in multiple sclerosis

Charity Evans, Feng Zhu, Elaine Kingwell, Afsaneh Shirani, Mia L. van der Kop, John Petkau, Paul Gustafson, Yinshan Zhao, Joel Oger, Helen Tremlett

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: A systematic evaluation of hospital events can be an important surrogate measure for drug effectiveness or adverse effects. The purpose of this study was to examine the association between beta-interferon use and hospital events in a large cohort of patients with multiple sclerosis (MS). Methods: Retrospective cohort study comparing beta-interferon exposed and unexposed patients using clinical data from the British Columbia MS (BCMS) database linked with health administrative databases, 1996-2008. For each patient, the primary outcome was the number of hospital events in each month, analyzed by quasi Poisson regression. Beta-interferon exposure was examined two ways: current and cumulative exposure. Secondary outcomes included whether a hospital event occurred in each month for each specific primary diagnoses, grouped by International Classification of Diseases categories. Results: Current exposure to beta-interferon was not associated with an altered rate of hospital events (adjusted incident rate ratio 1.018; 95% CI 0.803-1.290). Similarly, there was no association with cumulative exposure. Cumulative beta-interferon exposure was associated with a lower odds of respiratory disease-related hospital events compared to those never exposed to beta-interferon. Conclusions: Exposure to beta-interferon for MS was not associated with a change in overall hospital event rates. Preliminary evidence suggests that the beta-interferons may have a protective effect against respiratory diseases requiring hospitalization in MS patients.

Original languageEnglish (US)
Pages (from-to)1213-1222
Number of pages10
JournalPharmacoepidemiology and Drug Safety
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Interferon-beta
Multiple Sclerosis
Databases
British Columbia
International Classification of Diseases
Hospitalization
Cohort Studies
Retrospective Studies
Health
Pharmaceutical Preparations

Keywords

  • Beta-interferon
  • Hospitalization
  • Multiple sclerosis
  • Pharmacoepidemiology

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)

Cite this

Evans, C., Zhu, F., Kingwell, E., Shirani, A., van der Kop, M. L., Petkau, J., ... Tremlett, H. (2014). Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiology and Drug Safety, 23(11), 1213-1222. https://doi.org/10.1002/pds.3667

Association between beta-interferon exposure and hospital events in multiple sclerosis. / Evans, Charity; Zhu, Feng; Kingwell, Elaine; Shirani, Afsaneh; van der Kop, Mia L.; Petkau, John; Gustafson, Paul; Zhao, Yinshan; Oger, Joel; Tremlett, Helen.

In: Pharmacoepidemiology and Drug Safety, Vol. 23, No. 11, 01.11.2014, p. 1213-1222.

Research output: Contribution to journalArticle

Evans, C, Zhu, F, Kingwell, E, Shirani, A, van der Kop, ML, Petkau, J, Gustafson, P, Zhao, Y, Oger, J & Tremlett, H 2014, 'Association between beta-interferon exposure and hospital events in multiple sclerosis', Pharmacoepidemiology and Drug Safety, vol. 23, no. 11, pp. 1213-1222. https://doi.org/10.1002/pds.3667
Evans, Charity ; Zhu, Feng ; Kingwell, Elaine ; Shirani, Afsaneh ; van der Kop, Mia L. ; Petkau, John ; Gustafson, Paul ; Zhao, Yinshan ; Oger, Joel ; Tremlett, Helen. / Association between beta-interferon exposure and hospital events in multiple sclerosis. In: Pharmacoepidemiology and Drug Safety. 2014 ; Vol. 23, No. 11. pp. 1213-1222.
@article{f728e9de9c734fedb55202b4ad9b77cb,
title = "Association between beta-interferon exposure and hospital events in multiple sclerosis",
abstract = "Purpose: A systematic evaluation of hospital events can be an important surrogate measure for drug effectiveness or adverse effects. The purpose of this study was to examine the association between beta-interferon use and hospital events in a large cohort of patients with multiple sclerosis (MS). Methods: Retrospective cohort study comparing beta-interferon exposed and unexposed patients using clinical data from the British Columbia MS (BCMS) database linked with health administrative databases, 1996-2008. For each patient, the primary outcome was the number of hospital events in each month, analyzed by quasi Poisson regression. Beta-interferon exposure was examined two ways: current and cumulative exposure. Secondary outcomes included whether a hospital event occurred in each month for each specific primary diagnoses, grouped by International Classification of Diseases categories. Results: Current exposure to beta-interferon was not associated with an altered rate of hospital events (adjusted incident rate ratio 1.018; 95{\%} CI 0.803-1.290). Similarly, there was no association with cumulative exposure. Cumulative beta-interferon exposure was associated with a lower odds of respiratory disease-related hospital events compared to those never exposed to beta-interferon. Conclusions: Exposure to beta-interferon for MS was not associated with a change in overall hospital event rates. Preliminary evidence suggests that the beta-interferons may have a protective effect against respiratory diseases requiring hospitalization in MS patients.",
keywords = "Beta-interferon, Hospitalization, Multiple sclerosis, Pharmacoepidemiology",
author = "Charity Evans and Feng Zhu and Elaine Kingwell and Afsaneh Shirani and {van der Kop}, {Mia L.} and John Petkau and Paul Gustafson and Yinshan Zhao and Joel Oger and Helen Tremlett",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/pds.3667",
language = "English (US)",
volume = "23",
pages = "1213--1222",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Association between beta-interferon exposure and hospital events in multiple sclerosis

AU - Evans, Charity

AU - Zhu, Feng

AU - Kingwell, Elaine

AU - Shirani, Afsaneh

AU - van der Kop, Mia L.

AU - Petkau, John

AU - Gustafson, Paul

AU - Zhao, Yinshan

AU - Oger, Joel

AU - Tremlett, Helen

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose: A systematic evaluation of hospital events can be an important surrogate measure for drug effectiveness or adverse effects. The purpose of this study was to examine the association between beta-interferon use and hospital events in a large cohort of patients with multiple sclerosis (MS). Methods: Retrospective cohort study comparing beta-interferon exposed and unexposed patients using clinical data from the British Columbia MS (BCMS) database linked with health administrative databases, 1996-2008. For each patient, the primary outcome was the number of hospital events in each month, analyzed by quasi Poisson regression. Beta-interferon exposure was examined two ways: current and cumulative exposure. Secondary outcomes included whether a hospital event occurred in each month for each specific primary diagnoses, grouped by International Classification of Diseases categories. Results: Current exposure to beta-interferon was not associated with an altered rate of hospital events (adjusted incident rate ratio 1.018; 95% CI 0.803-1.290). Similarly, there was no association with cumulative exposure. Cumulative beta-interferon exposure was associated with a lower odds of respiratory disease-related hospital events compared to those never exposed to beta-interferon. Conclusions: Exposure to beta-interferon for MS was not associated with a change in overall hospital event rates. Preliminary evidence suggests that the beta-interferons may have a protective effect against respiratory diseases requiring hospitalization in MS patients.

AB - Purpose: A systematic evaluation of hospital events can be an important surrogate measure for drug effectiveness or adverse effects. The purpose of this study was to examine the association between beta-interferon use and hospital events in a large cohort of patients with multiple sclerosis (MS). Methods: Retrospective cohort study comparing beta-interferon exposed and unexposed patients using clinical data from the British Columbia MS (BCMS) database linked with health administrative databases, 1996-2008. For each patient, the primary outcome was the number of hospital events in each month, analyzed by quasi Poisson regression. Beta-interferon exposure was examined two ways: current and cumulative exposure. Secondary outcomes included whether a hospital event occurred in each month for each specific primary diagnoses, grouped by International Classification of Diseases categories. Results: Current exposure to beta-interferon was not associated with an altered rate of hospital events (adjusted incident rate ratio 1.018; 95% CI 0.803-1.290). Similarly, there was no association with cumulative exposure. Cumulative beta-interferon exposure was associated with a lower odds of respiratory disease-related hospital events compared to those never exposed to beta-interferon. Conclusions: Exposure to beta-interferon for MS was not associated with a change in overall hospital event rates. Preliminary evidence suggests that the beta-interferons may have a protective effect against respiratory diseases requiring hospitalization in MS patients.

KW - Beta-interferon

KW - Hospitalization

KW - Multiple sclerosis

KW - Pharmacoepidemiology

UR - http://www.scopus.com/inward/record.url?scp=84920451315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920451315&partnerID=8YFLogxK

U2 - 10.1002/pds.3667

DO - 10.1002/pds.3667

M3 - Article

C2 - 24953054

AN - SCOPUS:84920451315

VL - 23

SP - 1213

EP - 1222

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 11

ER -